Amgen shares fell 5.4% in the premarket; late-stage clinical trials of rival Novartis cholesterol drugs failed.

Zhitongcaijing · 1d ago
Amgen shares fell 5.4% in the premarket; late-stage clinical trials of rival Novartis cholesterol drugs failed.